Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNMNASDAQ:BTAINASDAQ:ELYMNASDAQ:HOWL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.43+10.0%$1.29$1.03▼$10.24$44.61M-0.27505,753 shs810,625 shsBTAIBioXcel Therapeutics$1.99+1.5%$2.09$1.29▼$42.72$10.92M0.641.17 million shs95,623 shsELYMEliem Therapeutics$1.27-2.3%$1.32$2.35▼$11.55$37.79M-0.39486,688 shs241,645 shsHOWLWerewolf Therapeutics$0.84-0.5%$1.00$0.60▼$6.74$37.66M0.48389,243 shs109,049 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-0.76%+8.33%-28.18%+0.78%-83.40%BTAIBioXcel Therapeutics+4.81%+14.62%-7.55%-64.38%-95.34%ELYMEliem Therapeutics0.00%+0.79%-0.78%-34.20%-68.09%HOWLWerewolf Therapeutics-5.18%+1.78%-18.00%-36.97%-87.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNMActinium Pharmaceuticals1.454 of 5 stars3.40.00.00.01.70.00.6BTAIBioXcel Therapeutics4.4419 of 5 stars3.35.00.04.53.01.70.6ELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHOWLWerewolf Therapeutics2.1481 of 5 stars3.51.00.00.01.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 2.80Moderate Buy$7.40417.48% UpsideBTAIBioXcel Therapeutics 2.67Moderate Buy$42.602,040.70% UpsideELYMEliem Therapeutics 0.00N/AN/AN/AHOWLWerewolf Therapeutics 3.00Buy$9.00971.43% UpsideCurrent Analyst Ratings BreakdownLatest BTAI, ELYM, ATNM, and HOWL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/1/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/25/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/19/2025BTAIBioXcel TherapeuticsRODMAN&RENSHAWSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/19/2025BTAIBioXcel TherapeuticsRodman & RenshawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.003/18/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/12/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/12/2025HOWLWerewolf TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/11/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.001/30/2025BTAIBioXcel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $48.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium Pharmaceuticals$81K550.74N/AN/A$1.31 per share1.09BTAIBioXcel Therapeutics$2.27M4.82N/AN/A($30.21) per share-0.07ELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AHOWLWerewolf Therapeutics$1.89M19.98N/AN/A$3.08 per share0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.39N/AN/AN/AN/A-100.85%-47.89%N/ABTAIBioXcel Therapeutics-$179.05M-$25.97N/AN/AN/A-3,119.33%N/A-105.04%5/8/2025 (Estimated)ELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/AHOWLWerewolf Therapeutics-$37.37M-$1.66N/AN/AN/A-578.80%-58.83%-38.45%5/2/2025 (Estimated)Latest BTAI, ELYM, ATNM, and HOWL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025BTAIBioXcel Therapeutics-$2.72N/AN/AN/A$0.35 millionN/A5/2/2025Q1 2025HOWLWerewolf Therapeutics-$0.44N/AN/AN/AN/AN/A3/27/2025Q4 2024BTAIBioXcel Therapeutics-$4.36-$3.57+$0.79-$3.57$0.72 million$0.30 million3/11/2025Q4 2024HOWLWerewolf Therapeutics-$0.43-$0.46-$0.03-$0.46$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25BTAIBioXcel TherapeuticsN/A1.871.81ELYMEliem TherapeuticsN/A60.4160.41HOWLWerewolf Therapeutics0.2910.1010.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%BTAIBioXcel Therapeutics30.68%ELYMEliem Therapeutics69.76%HOWLWerewolf Therapeutics64.84%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%BTAIBioXcel Therapeutics21.20%ELYMEliem Therapeutics4.70%HOWLWerewolf Therapeutics21.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableBTAIBioXcel Therapeutics905.49 million2.44 millionOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableHOWLWerewolf Therapeutics4044.83 million35.16 millionOptionableBTAI, ELYM, ATNM, and HOWL HeadlinesRecent News About These CompaniesEarnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to DeclineApril 25, 2025 | zacks.comWerewolf Therapeutics appoints Bloom as Chief Business OfficerApril 17, 2025 | markets.businessinsider.comWerewolf Therapeutics Appoints Steven Bloom as Chief Business OfficerApril 17, 2025 | quiverquant.comWerewolf Therapeutics Appoints Steven Bloom as Chief Business OfficerApril 17, 2025 | globenewswire.comWatch: First dire wolf’s howl for 10,000 years after scientists bring extinct species ‘back to life’April 8, 2025 | msn.comWerewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comWerewolf Therapeutics (HOWL) Gets a Buy from Bank of America SecuritiesMarch 28, 2025 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Werewolf Therapeutics (HOWL), Exelixis (EXEL)March 13, 2025 | markets.businessinsider.comWerewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with ChinaMarch 12, 2025 | tipranks.comWerewolf Therapeutics Reports 2024 Financial Results and ProgressMarch 12, 2025 | tipranks.comWerewolf Therapeutics reports Q4 EPS (46c), consensus (31c)March 11, 2025 | markets.businessinsider.comWerewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 11, 2025 | globenewswire.comWerewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma ConferenceMarch 4, 2025 | globenewswire.comWerewolf Therapeutics appoints Anil Singhal to board of directorsFebruary 24, 2025 | markets.businessinsider.comWerewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of DirectorsFebruary 24, 2025 | globenewswire.comWerewolf Therapeutics price target lowered to $4 from $12 at JMP SecuritiesJanuary 14, 2025 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Werewolf Therapeutics (HOWL)January 14, 2025 | markets.businessinsider.comWerewolf Therapeutics provides business update, highlights 2025 outlookJanuary 14, 2025 | markets.businessinsider.comBuy Rating Affirmed for Werewolf Therapeutics Amid Strategic Advancements and Strong Financial PositionJanuary 14, 2025 | markets.businessinsider.comWerewolf Therapeutics, Inc.: Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic OutlookJanuary 13, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBTAI, ELYM, ATNM, and HOWL Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.43 +0.13 (+10.00%) Closing price 04:00 PM EasternExtended Trading$1.49 +0.06 (+4.27%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.BioXcel Therapeutics NASDAQ:BTAI$1.99 +0.03 (+1.53%) Closing price 04:00 PM EasternExtended Trading$1.98 -0.01 (-0.75%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Eliem Therapeutics NASDAQ:ELYM$1.27 -0.03 (-2.31%) As of 04/25/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Werewolf Therapeutics NASDAQ:HOWL$0.84 0.00 (-0.54%) Closing price 04:00 PM EasternExtended Trading$0.84 +0.00 (+0.12%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
